Video: Marty Tenenbaum Speaks at the ALCF's Lung Cancer Living Room Event

Earlier this year, Cancer Commons founder Marty Tenenbaum, PhD, spoke at the Bonnie J. Addario Lung Cancer Foundation’s (ALCF) monthly Lung Cancer Living Room event. Marty’s own cancer diagnosis and treatment journey inspired his current mission: to make sure critical information is shared and gets to the patients who need it. By collecting data from thousands of patient-donated lung cancer stories, Cancer Commons can begin to show patients and doctors patterns in treatment choices, side effects, quality of life, outcomes, and more.

The video from the event is now available:

Lung Cancer Living Room 04-22-14 from Peninsula TV on Vimeo.

The ALCF, one of our partner organizations, works directly with individual lung cancer patients to ensure they each receive the best possible care. The Lung Cancer Living Room is a monthly in-person and online support group event that informs patients about lung cancer.

Click here for more information, including how to attend in person (in San Carlos, CA) or online. Click here to read the description of Marty’s upcoming event.


Foundation Medicine: Partners with the Addario Lung Cancer Medical Institute for Innovative Prospective Study Linking the Genomic Drivers of Lung Cancer in Young Adults with Treatment Options

“Foundation Medicine, Inc. (NASDAQ: FMI) today announced that it has partnered with the Addario Lung Cancer Medical Institute (ALCMI) and Bonnie J. Addario Lung Cancer Foundation (ALCF) to launch a first of its kind, multi-center, international prospective study, the Genomics of Young Lung Cancer. This study aims to better inform treatment decisions in young adults with lung cancer by leveraging FoundationOne®, the only commercially available and validated comprehensive genomic profile, to look beyond the genomic alterations commonly associated with lung cancer and identify the novel and unique alterations that present in lung cancers in young adults. This insight, in combination with the expertise of leading academic institutions and peer-reviewed literature, will be applied to determine more effective treatment options and tailor therapies precisely for these distinct and underserved patients.

“In 2014, 224,000 new cases of lung cancer are expected to be diagnosed; 3,700 of these are expected to occur in patients under the age of 45. Eighty percent of new lung cancer diagnoses are made in former or never-smokers, and three percent of cancer diagnoses made in patients younger than 45 will be lung cancer1.

“ ‘Lung cancer presents in a unique manner in young adults, who often do not exhibit the characteristic symptoms and signs of a typical patient with lung cancer,’ said Steven Young, President and COO of ALCMI. ‘Despite an environment of rapidly expanding treatment options available for lung cancer, a lack of understanding of comprehensive testing for the molecular drivers of the disease specifically in young adults restricts the effective treatments available to patients at a tragically early stage in their lives. Through this initial study, we hope to address this gap in knowledge and access, and lay the groundwork to routinely identify more effective treatment options for these patients.’ ”